Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tariq Rana
University of California, San Diego, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
ViRx Pharmaceuticals, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Rana is a co-founder of ViRx Pharmaceuticals, LLC (ViRx) and holds (b)(4) of equity interest. The mission of the company is to develop broad-spectrum antiviral therapeutics. Per Dr. Rana, there is no capitalization or board at this stage. The company plans to license intellectual property from the University that was developed in Dr. Rana's lab. This project is to define the role of small RNAs, RNP complexer containing APOBEC3G, and their subcellular context in modulating the HIV-1 life cycle. These studies will offer potential to explore host-pathogen interactions at the mechanistic levels, and develop new therapeutics for viral infections.
Mechanisms of innate immunity against HIV
The human host is invaded by a wide range of microbial pathogens and has evolved a number of defensive mechanisms to survive these infections. Recent studies have revealed that a host protein, APOBEC3G, exhibits the most potent block to HIV-1 replication. A second innate immune mechanism of defense against viral infections in plants and invertebrates involves RNAi. Experiments in the proposed work would decipher the mechanisms of these two innate immune responses to HIV-1 infection. Results of these studies would offer tremendous potential to not only explore host-pathogen interactions at the mechanistic levels, but also to develop new therapeutics for viral infections. Small molecules that interfere with interactions of a viral protein with APOBEC3G complexes could provide new drugs for AIDS therapy. In addition, cellular genes that are modulated by RNAI machinery during HIV infection would identify new candidates for drug development.
Filed on March 27, 2017.
Tell us what you know about Tariq Rana's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Tariq Rana filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Tariq Rana | University of California, San Diego | Conflict of Interest | ViRx Pharmaceuticals, LLC | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.